116 related articles for article (PubMed ID: 26840759)
1. A facile route to core-shell nanoparticulate formation of arsenic trioxide for effective solid tumor treatment.
Zhang Z; Liu H; Zhou H; Zhu X; Zhao Z; Chi X; Shan H; Gao J
Nanoscale; 2016 Feb; 8(7):4373-80. PubMed ID: 26840759
[TBL] [Abstract][Full Text] [Related]
2. RGD conjugated liposome-hollow silica hybrid nanovehicles for targeted and controlled delivery of arsenic trioxide against hepatic carcinoma.
Fei W; Zhang Y; Han S; Tao J; Zheng H; Wei Y; Zhu J; Li F; Wang X
Int J Pharm; 2017 Mar; 519(1-2):250-262. PubMed ID: 28109899
[TBL] [Abstract][Full Text] [Related]
3. Real-time monitoring of arsenic trioxide release and delivery by activatable T(1) imaging.
Zhao Z; Wang X; Zhang Z; Zhang H; Liu H; Zhu X; Li H; Chi X; Yin Z; Gao J
ACS Nano; 2015 Mar; 9(3):2749-59. PubMed ID: 25688714
[TBL] [Abstract][Full Text] [Related]
4. pH-triggered sustained release of arsenic trioxide by polyacrylic acid capped mesoporous silica nanoparticles for solid tumor treatment in vitro and in vivo.
Xiao X; Liu Y; Guo M; Fei W; Zheng H; Zhang R; Zhang Y; Wei Y; Zheng G; Li F
J Biomater Appl; 2016 Jul; 31(1):23-35. PubMed ID: 27059495
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide in the management of acute promyelocytic leukaemia.
Mathews V; Chandy M; Srivastava A
Natl Med J India; 2001; 14(4):215-22. PubMed ID: 11547528
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies.
Tallman MS
Blood Rev; 2001 Sep; 15(3):133-42. PubMed ID: 11735161
[No Abstract] [Full Text] [Related]
7. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
Douer D; Tallman MS
J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
[TBL] [Abstract][Full Text] [Related]
8. [The effect and mechanism of arsenic trioxide on hepatocellular carcinoma].
Liu LX; Zhu AL; Chen W; Guo HX; Wang XQ; Liu ZH; Zhang TD; Jiang HC; Wu M
Zhonghua Wai Ke Za Zhi; 2005 Jan; 43(1):33-6. PubMed ID: 15774171
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of arsenic trioxide-loaded albumin nanoparticles as carriers: preparation and antitumor efficacy.
Yang Z; Yang M; Peng J
Drug Dev Ind Pharm; 2008 Aug; 34(8):834-9. PubMed ID: 18622876
[TBL] [Abstract][Full Text] [Related]
10. A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer.
Ahn RW; Chen F; Chen H; Stern ST; Clogston JD; Patri AK; Raja MR; Swindell EP; Parimi V; Cryns VL; O'Halloran TV
Clin Cancer Res; 2010 Jul; 16(14):3607-17. PubMed ID: 20519360
[TBL] [Abstract][Full Text] [Related]
11. The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells.
Chen X; Zhang M; Liu LX
Oncol Rep; 2009 Jul; 22(1):73-80. PubMed ID: 19513507
[TBL] [Abstract][Full Text] [Related]
12. Targeted arsenite-loaded magnetic multifunctional nanoparticles for treatment of hepatocellular carcinoma.
Chi X; Zhang R; Zhao T; Gong X; Wei R; Yin Z; Lin H; Li D; Shan H; Gao J
Nanotechnology; 2019 Apr; 30(17):175101. PubMed ID: 30654348
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of arsenic trioxide in murine xenograft model.
Kito M; Matsumoto K; Wada N; Sera K; Futatsugawa S; Naoe T; Nozawa Y; Akao Y
Cancer Sci; 2003 Nov; 94(11):1010-4. PubMed ID: 14611680
[TBL] [Abstract][Full Text] [Related]
14. Identification of Arsenic Direct-Binding Proteins in Acute Promyelocytic Leukaemia Cells.
Zhang T; Lu H; Li W; Hu R; Chen Z
Int J Mol Sci; 2015 Nov; 16(11):26871-9. PubMed ID: 26569224
[TBL] [Abstract][Full Text] [Related]
15. Delivery of Arsenic Trioxide by Multifunction Nanoparticles To Improve the Treatment of Hepatocellular Carcinoma.
Wu Q; Chen X; Wang P; Wu Q; Qi X; Han X; Chen L; Meng X; Xu K
ACS Appl Mater Interfaces; 2020 Feb; 12(7):8016-8029. PubMed ID: 31997633
[TBL] [Abstract][Full Text] [Related]
16. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
Lengfelder E; Hofmann WK; Nowak D
Leukemia; 2012 Mar; 26(3):433-42. PubMed ID: 21904379
[TBL] [Abstract][Full Text] [Related]
17. Inhibition factors of arsenic trioxide therapeutic effects in patients with acute promyelocytic leukemia.
Sui M; Zhang Z; Zhou J
Chin Med J (Engl); 2014; 127(19):3503-6. PubMed ID: 25269921
[TBL] [Abstract][Full Text] [Related]
18. Icariin synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.
Li W; Wang M; Wang L; Ji S; Zhang J; Zhang C
Cell Biochem Biophys; 2014 Mar; 68(2):427-36. PubMed ID: 23975599
[TBL] [Abstract][Full Text] [Related]
19. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
[TBL] [Abstract][Full Text] [Related]
20. Significance of intracellular arsenic trioxide for therapeutic response in acute promyelocytic leukemia.
Sahu GR; Jena RK
Am J Hematol; 2005 Feb; 78(2):113-6. PubMed ID: 15682419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
